Vitamin K exists in two primary vitamer forms: Vitamin K1 (phylloquinone) and Vitamin K2 (menaquinone). While historically grouped together under the umbrella of coagulation regulation, modern research demonstrates that these forms differ significantly in chemical structure, pharmacokinetics, and tissue specificity.
Menaquinones (K2) represent up to 25% of total dietary vitamin K intake. Their distinct side-chain structures yield superior bioavailability and a longer half-life than phylloquinones. Consequently, K2 is more effective at activating extra-hepatic, vitamin K-dependent proteins that are critical to cardiovascular and skeletal health.
| Health Metric | Clinical Findings & Mechanism |
| Cardiovascular Health | Inhibits arterial calcification. Observational data shows a 52% reduction in artery calcification and a 57% reduction in cardiovascular mortality in cohorts with high K2 intake. |
| Bone & Dental Metabolism | Essential for calcium homeostasis. K2 activates osteocalcin, slowing age-related bone mineral density decline and supporting dental health. |
| Immunomodulation | Demonstrates the ability to inhibit T-cell proliferation and modulate systemic immune responses. |
| Oncology (Adjunct) | Clinical trials indicate K2 may reduce recurrence rates and extend survival times in liver cancer patients. |
Current Dietary Reference Values (DRVs) are exclusively based on Vitamin K1’s role in hepatic coagulation. However, growing evidence underscores the need to update these guidelines to reflect Vitamin K2’s distinct systemic benefits, specifically its roles in supporting cardiovascular health and bone mineralization via protein activation. Although long-term controlled trials are ongoing, the underlying biological mechanisms supporting K2’s efficacy are robust and well-established.
The content of this post is provided for informational purposes only and is not intended as medical advice, or as a substitute for the medical advice of your physician.